ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS)
BOSTON, MA, USA and LONDON, UK I August 27, 2024 I Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that preclinical data from a non-human primate (NHP) study of ORX142, a highly potent and selective orexin receptor 2 (OX2R) agonist being developed to address excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders, has been accepted for a late- breaking poster presentation at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) being held September 24-27, 2024, in Seville, Spain.
The poster presentation will feature, for the first time, robust preclinical data demonstrating that low doses of ORX142 promoted wakefulness in non-human primates in a highly predictive and translational model.
“ORX142 is the second drug candidate from our growing pipeline of potentially best-in-class OX2R agonists that has shown significant activity in promoting wakefulness at very low doses in highly predictive and translational preclinical models,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. “We believe these non-human primate data are compelling as they demonstrate the potential for ORX142, a highly potent and novel OX2R agonist, to alleviate excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders with no significant loss of orexin. We are thrilled to be sharing these preclinical data in a late-breaking presentation at Sleep Europe 2024.”
Details of the poster presentation are as follows:
Title: ORX142, an Oral, Highly Potent and Selective Orexin Receptor 2 Agonist, Promotes Wakefulness in Non-Human Primates
Poster Number: P5073
Authors: Sarah Wurts Black, Tod Steinfeld, Karl Gibson, Emiliangelo Ratti, David Grainger, Mario Alberto Accardi, and Deborah S. Hartman
Poster Presentation: Thursday, September 26th at 12:00 – 13:30 and 17:30 – 18:45 (local time)
Additional meeting information can be found on the Sleep Europe 2024 website at https://esrs.eu/sleep-congress/. The abstracts are expected to be published approximately two weeks prior to the start of the conference. The poster will also be available on the Centessa website at https://investors.centessa.com/events-presentations after the conference concludes.
About Centessa’s Orexin Agonist Program
Orexin is a neuropeptide that regulates the sleep-wake cycle, leading to arousal and promoting wakefulness. Low levels of orexin result in excessive daytime sleepiness (EDS) and poor regulation of rapid eye movement (REM) sleep and, in narcolepsy type 1 (NT1), cataplexy and other symptoms. Centessa is developing a pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists intended to be orally administered for sleep-wake disorders, including NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), with therapeutic potential to alleviate EDS in select neurological, neurodegenerative, and psychiatric conditions. The Company’s lead asset, ORX750, is in a Phase 1 clinical study. ORX750 and ORX142 have not been approved by the FDA or any other regulatory authority.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.
SOURCE: Centessa Pharmaceuticals
Post Views: 2,160
ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS)
BOSTON, MA, USA and LONDON, UK I August 27, 2024 I Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that preclinical data from a non-human primate (NHP) study of ORX142, a highly potent and selective orexin receptor 2 (OX2R) agonist being developed to address excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders, has been accepted for a late- breaking poster presentation at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) being held September 24-27, 2024, in Seville, Spain.
The poster presentation will feature, for the first time, robust preclinical data demonstrating that low doses of ORX142 promoted wakefulness in non-human primates in a highly predictive and translational model.
“ORX142 is the second drug candidate from our growing pipeline of potentially best-in-class OX2R agonists that has shown significant activity in promoting wakefulness at very low doses in highly predictive and translational preclinical models,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. “We believe these non-human primate data are compelling as they demonstrate the potential for ORX142, a highly potent and novel OX2R agonist, to alleviate excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders with no significant loss of orexin. We are thrilled to be sharing these preclinical data in a late-breaking presentation at Sleep Europe 2024.”
Details of the poster presentation are as follows:
Title: ORX142, an Oral, Highly Potent and Selective Orexin Receptor 2 Agonist, Promotes Wakefulness in Non-Human Primates
Poster Number: P5073
Authors: Sarah Wurts Black, Tod Steinfeld, Karl Gibson, Emiliangelo Ratti, David Grainger, Mario Alberto Accardi, and Deborah S. Hartman
Poster Presentation: Thursday, September 26th at 12:00 – 13:30 and 17:30 – 18:45 (local time)
Additional meeting information can be found on the Sleep Europe 2024 website at https://esrs.eu/sleep-congress/. The abstracts are expected to be published approximately two weeks prior to the start of the conference. The poster will also be available on the Centessa website at https://investors.centessa.com/events-presentations after the conference concludes.
About Centessa’s Orexin Agonist Program
Orexin is a neuropeptide that regulates the sleep-wake cycle, leading to arousal and promoting wakefulness. Low levels of orexin result in excessive daytime sleepiness (EDS) and poor regulation of rapid eye movement (REM) sleep and, in narcolepsy type 1 (NT1), cataplexy and other symptoms. Centessa is developing a pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists intended to be orally administered for sleep-wake disorders, including NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), with therapeutic potential to alleviate EDS in select neurological, neurodegenerative, and psychiatric conditions. The Company’s lead asset, ORX750, is in a Phase 1 clinical study. ORX750 and ORX142 have not been approved by the FDA or any other regulatory authority.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.
SOURCE: Centessa Pharmaceuticals
Post Views: 2,160
